Aprea Therapeutics (APRE)
(Delayed Data from NSDQ)
$4.30 USD
+0.07 (1.55%)
Updated Jun 14, 2024 09:45 AM ET
3-Hold of 5 3
F Value F Growth C Momentum F VGM
Brokerage Reports
Aprea Therapeutics, Inc. [APRE]
Reports for Purchase
Showing records 21 - 40 ( 59 total )
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; ATRN-119 Ph1 Data in 4Q:23; ATRN-1051 IND Filing by YE:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2Q23 Results; Continued Execution Across Programs; First Look at Phase 1 ATRN-119 Data Expected 4Q23
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q1 Financials; ATRN-119 Clinical Data in Q1:24; ATRN-1051 IND by YE:23
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
1Q23 Results; ATRNs Progressing as Planned; 1051?s IND Filing by YE23 Followed by 119?s Phase 1/2 Data in 1Q24
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology- Roundup for 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Roundup For 2023 AACR Meeting
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
2022 Results; Warming up for ATRN-119's Phase 1/2 Data; Split-Adjusted Price Target to $20
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology -AACR 2023 Abstract Roundup For Covered Companies
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
First Patient Dosed in ATRN-119's Phase 1/2 Trial in DDR-Mutant Solid Tumors; Preliminary Data in 2023
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q3 Financials; ATR Inhibitor ATRN-119 Study Ongoing
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
3Q22 Results; ATRN-119 Phase1/2 Pushes Forward; ATRN-W1051 Progressing Towards IND
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Look Different, Act Different, Differentiate on New ATR Thesis; Assuming Coverage at Buy and $3 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: PANTGINIS J
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Relevant Abstracts at SITC 2022
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Relevant Abstracts at EORTC-NCI-AACR 2022
Provider: Wedbush Securities Inc.
Analyst: NIERENGARTEN D
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Reports of the Death of Synthetic Lethality are Grossly Exaggerated
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Company: Aprea Therapeutics, Inc.
Industry: Medical - Biomedical and Genetics
Q2 Financials; ATRi ATRN-119 Ph 1 Set to Initiate
Provider: Wedbush Securities Inc.
Analyst: DRISCOLL R